ONCOLYTICS BIOTECH INCONCY
ASignal's systematic analysis rates ONCY as Bearish.
Reflects the latest available analysis · analyzed Oct 22, 2026
The case on ONCY
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near oversold level (31.45) suggesting potential downside protection
- Positive MACD histogram indicating slight momentum improvement
- Cash position ($4.12M) exceeds total debt ($448,000), providing limited runway
- Negative price momentum (-0.107) and trading below both SMA20 and SMA50
- Extremely weak margins: gross, operating, and net margins all at 0%
- Negative return on assets (-211.24%) indicating severe profitability issues
- Negative free cash flow ($-12.01M) and negative operating cash flow ($-26.70M)
- Negative enterprise value to EBITDA (-1.64x) and negative forward P/E (-2.51x) signaling deep financial distress
- Price to book ratio of -10.21x indicates liabilities exceed asset value
See the full verdict on ONCY
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ONCY
Most investors never get a second opinion, let alone several. ASignal runs ONCY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.